Bevacizumab 10 mg/kg

DRUG2 trials

Sponsors

Hoffmann-La Roche, Corcept Therapeutics

Conditions

Advanced Liver CancersEndometrial CancerFallopian Tube CancerOvarian CancerPeritoneal Neoplasms

Phase 1

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

RecruitingNCT04524871

Hoffmann-La RocheAdvanced Liver Cancers

Start: 2020-11-01End: 2027-12-31Target: 518Updated: 2026-03-27

Phase 2

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

RecruitingNCT06906341

Corcept TherapeuticsEndometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer +1

Start: 2025-04-11End: 2026-12-31Target: 270Updated: 2025-10-22

Related Papers

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.

2025-01-2141 citations

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Cancer Research Communications2024-03-2914 citations

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Journal for ImmunoTherapy of Cancer2023-06-0183 citations

Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).

Journal of Clinical Oncology2023-06-0149 citations